Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mechanisms of action of OPC-28326, a selective hindlimb vasodilator.
Orito K, Imaizumi T, Yoshida K, Fujiki H, Kishi M, Teramoto S, Tanaka M, Shimizu H, Tominaga M, Kimura Y, Kambayashi J, Mori T. Orito K, et al. Among authors: shimizu h. J Pharmacol Exp Ther. 1999 Nov;291(2):604-11. J Pharmacol Exp Ther. 1999. PMID: 10525078
A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-Host Disease by National Institutes of Health Criteria in a Japanese Cohort.
Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, Tachibana T, Fujisawa S, Nakajima Y, Numata A, Toyosaki M, Aoyama Y, Onizuka M, Hagihara M, Koyama S, Kanda Y, Nakasone H, Shimizu H, Kato S, Watanabe R, Shono K, Sakai R, Saito T, Nakaseko C, Okamoto S. Ohwada C, et al. Among authors: shimizu h. Biol Blood Marrow Transplant. 2020 Jan;26(1):162-170. doi: 10.1016/j.bbmt.2019.09.016. Epub 2019 Sep 16. Biol Blood Marrow Transplant. 2020. PMID: 31536824 Free article. Clinical Trial.
Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival.
Nakasone H, Kako S, Tachibana T, Tanaka M, Onizuka M, Takahashi S, Yokota A, Fujiwara SI, Sakura T, Sakaida E, Fujisawa S, Yamazaki R, Gotoh M, Hagihara M, Aotsuka N, Tsukada N, Hatta Y, Shimizu H, Usuki K, Watanabe R, Mori T, Yano S, Kanamori H, Kanda Y. Nakasone H, et al. Among authors: shimizu h. Transplant Cell Ther. 2021 Sep;27(9):800.e1-800.e8. doi: 10.1016/j.jtct.2021.06.020. Epub 2021 Jun 24. Transplant Cell Ther. 2021. PMID: 34171522 Free article.
Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
Kikuchi T, Mori T, Ohwada C, Onoda M, Shimizu H, Yokoyama H, Onizuka M, Koda Y, Kato J, Takeda Y, Hino Y, Mishina T, Sakaida E, Shono K, Nagao Y, Yokota A, Matsumoto K, Morita K, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Kikuchi T, et al. Among authors: shimizu h. Int J Hematol. 2021 Jan;113(1):128-133. doi: 10.1007/s12185-020-02990-y. Epub 2020 Sep 4. Int J Hematol. 2021. PMID: 32886279
Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study.
Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, Shono K, Tanaka M, Tsukamoto S, Mori T, Yamazaki E, Najima Y, Hangaishi A, Hoshino T, Watanabe R, Matsumoto K, Okamoto S; for Kanto Study Group for Cell Therapy (KSGCT). Kako S, et al. Among authors: shimizu h. Am J Hematol. 2020 Mar;95(3):251-257. doi: 10.1002/ajh.25693. Epub 2019 Dec 19. Am J Hematol. 2020. PMID: 31804748 Free article. Clinical Trial.
6,366 results